Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

ER+HER2- Breast Cancer 1

Interventions

Drug Therapy 107 Cisplatin 97 Radiotherapy 89 Carboplatin 87 Bevacizumab 79 Oxaliplatin 74 tislelizumab 68 Capecitabine 67 Cyclophosphamide 65 Gemcitabine 64 toripalimab 61 Paclitaxel 57 Specimen Handling 55 pembrolizumab 54 sintilimab 53 Surgical Procedures, Operative 52 anlotinib 49 Magnetic Resonance Spectroscopy 49 Fluorouracil 49 Immune Checkpoint Inhibitors 43 Blood Specimen Collection 42 130-nm albumin-bound paclitaxel 42 Standard of Care 39 camrelizumab 36 fludarabine 35 lenvatinib 34 Leucovorin 34 venetoclax 30 Radiosurgery 30 Immunotherapy 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × 18-O-demethylcervinomycin A2 × Clear all

NCT07109284 2025-08-07

NeoSaciA

West China Hospital

Phase 2 Not yet recruiting

ER+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡